Related Experiment Video
Updated: Jun 22, 2026
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
High-risk clinical stage I NSGCT: the case for RPLND
Christopher Morash1, Ilias Cagiannos
1Division of Urology, Department of Surgery, B3 Urology, The Ottawa Hospital, Ottawa, ON, K1Y 4E9, Canada. cmorash@ottawahospital.on.ca
Introduction:
High-risk clinical stage I NSGCT patients are at significant risk of harbouring occult metastatic disease. In these patients, treatment options consist of retroperitoneal lymph node dissection (RPLND) or two cycles of primary BEP chemotherapy. Both these options provide a nearly 100% cure rate.
Materials And Methods:
We review the rationale for both treatments.
Conclusions:
Advantages of RPLND include high cure rate with single modality therapy eliminating the need for chemotherapy with its attendant long-term toxicities in the majority of patients.
